MGMT and neoplasm: Since patients with MGMT overexpression in tumors respond more poorly to alkylating agents, co-administration of O6-BG to deplete the tumor pools of MGMT to enhance drug cytotoxicity has been previously attempted in a clinical setting [18, 19].